These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 11733477)

  • 1. Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones.
    Balcabao IP; Alou L; Aguilar L; Gomez-Lus ML; Giménez MJ; Prieto J
    J Antimicrob Chemother; 2001 Dec; 48(6):907-9. PubMed ID: 11733477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
    Joyanes P; Pascual A; Giménez MJ; García I; Aguilar L; Perea E
    Chemotherapy; 2001 Dec; 47(6):409-14. PubMed ID: 11786655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
    Fuentes F; Giménez MJ; Marco F; Alou L; Aguilar L; Prieto J
    Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):137-9. PubMed ID: 10746503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.
    Pérez-Trallero E; García-Rey C; Martín-Sánchez AM; Aguilar L; García-de-Lomas J; Ruiz J;
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2665-7. PubMed ID: 12121952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():107-10. PubMed ID: 10824041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
    Prieto J; Aguilar L; Fuentes F; Giménez MJ; Alou L; Dal-Ré R; Sörgel F; Frías J
    Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance.
    Pérez-Vázquez M; Román F; Varela MC; Cantón R; Campos J
    J Antimicrob Chemother; 2003 Jan; 51(1):147-51. PubMed ID: 12493800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
    Thorburn CE; Edwards DI
    J Antimicrob Chemother; 2001 Jul; 48(1):15-22. PubMed ID: 11418508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.
    Roychoudhury S; Twinem TL; Makin KM; McIntosh EJ; Ledoussal B; Catrenich CE
    J Antimicrob Chemother; 2001 Jul; 48(1):29-36. PubMed ID: 11418510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses.
    Fass RJ; Barnishan J
    J Antimicrob Chemother; 2001 Nov; 48(5):609-15. PubMed ID: 11679549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
    Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network.
    Buxbaum A; Straschil U; Moser C; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 1999 May; 43 Suppl B():13-8. PubMed ID: 10382870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.
    Lemmen S; Al-Lahham A; Lütticken R; Reinert RR
    Chemotherapy; 2001; 47(2):104-9. PubMed ID: 11173811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
    Lafredo SC; Foleno BD; Fu KP
    Chemotherapy; 1993; 39(1):36-9. PubMed ID: 8383031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.